CORRECTION article

Front. Bioeng. Biotechnol., 15 July 2025

Sec. Nanobiotechnology

Volume 13 - 2025 | https://doi.org/10.3389/fbioe.2025.1631667

Correction: Baicalin-modifed polyethylenimine for miR-34a efficient and safe delivery

  • YW

    Yingying Wang 1,2

  • BW

    Baiyan Wang 1

  • YX

    Yangfan Xiao 2

  • QC

    Qingchun Cai 3

  • JX

    Junyue Xing 2

  • HT

    Hao Tang 2*

  • RL

    Ruiqin Li 4*

  • HZ

    Hongtao Zhang 5,6,7,8*

  • 1. Medical College, Henan University of Chinese Medicine, Zhengzhou, Henan, China

  • 2. National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Heart Center of Henan Provincial People’s Hospital, Fuwai Central China Cardiovascular Hospital and Central China Branch of National Center for Cardiovascular Diseases, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, China

  • 3. Department of Clinical Lab, The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China

  • 4. Academy of Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou, Henan, China

  • 5. Blood Purification Center, The People’s Hospital of Zhengzhou University, Zhengzhou, China

  • 6. Blood Purification Center, Henan Provincial People’s Hospital, Zhengzhou, China

  • 7. Institute of Nephrology, Mathura, Henan, China

  • 8. Department of Nephrology Henan Provincial People’s Hospital, Zhengzhou, China

In the published article, there was an error in Western blot of Figure 4C as published. An extra GAPDH band image was included in the original Figure 4C. The corrected Western blot of Figure 4C and its caption FIGURE 4 BA-PEI/miR-34a induced apoptosis of tumor cell A549. (C) Western blots used to analyze the apoptotic protein (pro-caspase-3, -8, and -9 and PTEN), based on the control, miR-34a, PEI, BA-PEI, PEI/miR-34a, and BA-PEI/miR-34a. appear below.

FIGURE 4

The original version of this article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

baicalin, lung cancer, gene therapy, miR-34a, hydrophobic modification

Citation

Wang Y, Wang B, Xiao Y, Cai Q, Xing J, Tang H, Li R and Zhang H (2025) Correction: Baicalin-modifed polyethylenimine for miR-34a efficient and safe delivery. Front. Bioeng. Biotechnol. 13:1631667. doi: 10.3389/fbioe.2025.1631667

Received

20 May 2025

Accepted

30 June 2025

Published

15 July 2025

Volume

13 - 2025

Edited and reviewed by

Gianni Ciofani, Italian Institute of Technology (IIT), Italy

Updates

Copyright

*Correspondence: Hao Tang, ; Ruiqin Li, ; Hongtao Zhang,

† These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics